Even in couple of decades back, ‘Vaccines Market’ in India did not use to be considered as a focus area by many pharmaceutical companies. Commoditization of this market with low profit margin and unpredictable interest of the government/the doctors towards immunization were the main reasons. Large global players like Glaxo exited the vaccine market at that time by withdrawing products like, Tetanus Toxoid, Triple Antigen and other vaccines from the market.
Currently, the above scenario is fast changing. The vaccine market is getting rejuvenated not only with the National Immunization Program (NIP) of the country, but also with the emergence of newer domestic vaccines players and introduction of novel vaccines by the global players, which we shall discuss below.
In addition, the ‘Indian Academy of Pediatrics (IAP) Committee on Immunization’ now recommends the ‘best individual practices schedule’ for the children in consultation with their respective parents. Such schedule may not conform to NIP and include newer vaccines, broadening the scope of use of vaccines in general.
Global Market:
According to GBI Research Report, overall global vaccines market was valued at US$ 28 billion in 2010 and is expected to reach US$ 56.7 billion by 2017 with a CAGR of 11.5%. The key growth driver of this segment will be introduction of newer vaccines, which are currently either in the regulatory filing stage or in the late stages of clinical development.
The important international players in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer, Novartis AG, Merck and SP-MSD, representing around 88% of the total vaccine segment globally.
Indian Market:
|
Year |
Value Rs. Cr. |
Growth % |
|
2007 |
389 |
- |
|
2008 |
383 |
-2 |
|
2009 |
476 |
24 |
|
2010 |
726 |
53 |
Source: IMS – Health MAT June 2010
India is one of largest markets for all types of vaccines in the world. The growth is being driven by the new generation and combination vaccines, like DPT with Hepatitis B, Hepatitis A and Injectable polio vaccine. The demand for veterinary vaccines is also showing ascending trend. Pediatric vaccines contribute to around 60% of the total vaccines market in India.
McKinsey in its report titled, “India Pharma 2020: Propelling access and acceptance, realizing true potential“ stated that at 2% penetration, the vaccines market of India is significantly under-penetrated with an estimated turnover of around US$ 250 million, where the private segment accounts for two-thirds of the total. McKinsey expects the market to grow to US$ 1.7 billion by 2020.
In India companies like, Serum Institute, Shantha Biotecnics, Bharat Biotech and Panacea Biotech are poised to take greater strides in this direction. Bharat Biotech is incidentally the largest Hepatitis B vaccine producer in the world. Likewise, Serum Institute is reportedly one of the largest suppliers of vaccines to over a 130 countries of the world and claim that ’1 out of every 2 children immunized worldwide gets at least one vaccine produced by Serum Institute.’
Indian Vaccine Market: Domestic vs MNCs:
In the domestic vaccine market the market share of the Indian players is gradually improving as compared to their multinational counterparts.
| Types |
June 2009 MAT |
% Value Growth |
June 2010 MAT |
% Value Growth |
| Indian Companies |
55% |
27 |
59% |
64 |
| MNCs |
45% |
21 |
41% |
38 |
Source IMS-Health – June 2010 MAT
Indian Vaccine Market: Top 10 Companies:
|
Rank |
Company |
Value (Rs. Cr) |
%Market Share |
%Value Growth |
| Vaccine Market |
726 |
100 |
53 |
|
|
1 |
GSK |
131 |
18 |
23 |
|
2 |
Sanofi Aventis |
129 |
18 |
>> |
|
3 |
Pfizer |
71 |
10 |
75 |
|
4 |
Novartis |
68 |
9 |
-12 |
|
5 |
Serum Institute |
68 |
9 |
40 |
|
6 |
Panacea Biotech |
59 |
8 |
57 |
|
7 |
VHB Lifesciences |
33 |
5 |
>> |
|
8 |
Zydus Cadila |
32 |
4 |
56 |
|
9 |
MSD |
31 |
4 |
>> |
|
10 |
Shantha Biotech |
24 |
3 |
15 |
Source IMS-Health – June 2010 MAT
Indian Vaccine Market: Top Therapies:
| Therapies |
Value (Rs.Cr.) |
%Market Share |
% Value Growth |
Incr. Value (Rs. Cr) |
||
|
June’09 MAT |
June’10 MAT |
June’09 MAT |
June’10 MAT |
|||
| Vaccine Market |
726.1 |
100 |
24 |
53 |
93 |
250 |
| Toddler Vaccine |
211 |
29 |
55 |
60 |
47 |
79 |
| Adult Vaccine |
205 |
28 |
-4 |
22 |
-7 |
37 |
| Paediatric Combination Vaccines |
146 |
20 |
67 |
>> |
28 |
77 |
| Paediatric Single Vaccines |
131 |
18 |
25 |
32 |
20 |
32 |
| All Other Vaccines |
33 |
5 |
— |
431 |
6 |
27 |
Source IMS-Health – June 2010 MAT
Indian Vaccine Market: Top 10 Brands:
|
Rank |
Brands |
Company |
Value (Rs.Cr.) |
Value Growth % |
Incr. value (Rs. Cr.) |
||
|
June’09 Mat |
June’10 MAT |
June’09 Mat |
June’10 MAT |
||||
| Vaccine Market |
726 |
24 |
53 |
93.1 |
250 |
||
| 1 | Prevenar | Pfizer |
71 |
150 |
75 |
24 |
30 |
| 2 | Rabipur | Novartis |
68 |
4 |
-12 |
3 |
-9 |
| 3 | Pentaxim | Sanofi Aventis |
46 |
>> |
>> |
7 |
39 |
| 4 | Havrix | GSK |
37 |
9 |
47 |
2 |
12 |
| 5 | Varivax | VHB |
33 |
59 |
>> |
5 |
18 |
| 6 | Vaxirab | Zydus Cadila |
32 |
-11 |
56 |
-3 |
11 |
| 7 | Varil Rix | GSK |
25 |
-3 |
-9 |
-1 |
-2 |
| 8) | Gardasil | MSD |
22 |
—- |
>> |
5 |
16 |
| 9 | Verorab | Sanofi Aventis |
21 |
—- |
—- |
0 |
21 |
| 10 | Rotarix | GSK |
21 |
—- |
>> |
10 |
11 |
Source: IMS-Health – June 2010 MAT
Indian Vaccine Market: Top 10 New Introductions:
|
NIs |
Company |
Launch Date |
Value (Rs. Cr) |
Incr. Value (Rs. Cr) |
| Vaccine Market |
104 |
79 |
||
| Gardasil | MSD | 10/2008 |
22 |
16 |
| Rotarix | GSK | 07/2008 |
21 |
11 |
| Pentavac | Serum Institute | 10/2008 |
16 |
12 |
| Cervarix | GSK | 02/2009 |
11 |
10 |
| Polprotec | Panacea Biotech | 07/2008 |
9 |
6 |
| Xprab | Ranbaxy | 10/2009 |
7 |
7 |
| Quadrovax | Serum Institute | 11/2008 |
4 |
3 |
| Comvac- 5 | Bharat Biotech | 02/2009 |
3 |
3 |
| Pentavac – SD | Serum Institute | 11/2009 |
2 |
2 |
| Shan HIB- DPT | Shantha Biotech | 09/2008 |
2 |
1 |
Source:IMS-Health – June 2010 MAT
Action areas to boost growth:
McKinsey in its above report ‘India Pharma 2020’ indicated that the action in the following 4 areas by the vaccine players will drive the vaccine market growth in India:
- Companies need to go for local production of vaccines or leverage supply partnerships. GlaxoSmithKline’s local partnership for the HiB vaccine with Bio-manguinhos in Brazil has been cited as an example.
- Companies will need to conduct studies on the economic impact of vaccination and establish vaccine safety and performance standards.
- Extension of vaccine coverage beyond pediatricians and inclusion of general practitioners, consulting physicians and gynaecologists will be essential.
- Companies will need to enhance supply chain reliability and reduce costs.
Conclusions:
On January 7, 2012, while requesting the ‘Overseas Indian Medical Professionals’ to partner with the institutions in India, the Health Minister, in his address, announced that the Ministry of Health has already introduced the second dose of measles vaccine and Hepatitis-B vaccination across the country. Moreover, from December, 2011 a ‘Pentavalent Vaccine’ has been introduced, initially in 2 States, covering 1.5 million children of India.
All these augur quite well for the country. However, keeping in view of the humongous disease burden of India, immunization program with various types of vaccines should receive active encouragement from the government as disease prevention initiatives, at least, keeping the future generation in mind.
If such policy measures are initiated in the country, without delay, the domestic vaccine market , in turn, will receive further growth momentum, together with newer players and modern vaccines coming in, to help addressing effectively a significant area of the healthcare concerns of the country.
By: Tapan J Ray
Disclaimer: The views/opinions expressed in this article are entirely my own, written in my individual and personal capacity. I do not represent any other person or organization for this opinion.